RESEARCH GROUPS

Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS)

Overview

Team

Publications

Patents

Dissemination

crips-grup
29

Number of publications

62.07
%

% Q1

41.38
%

% D1

37.93
%

% Leadership

9.09
%

% Female Leadership

2.95

CROWN (2021-2025)

27.03
%

HCP10% (2021-2025)

65.52
%

% Open access

86.21
%

% International Collaboration

8

Highly cited papers / HCP 1% (2021-2025)

3

Publications in high-IF journals with high Altmetric scores

2

Number of Ongoing Projectes (total)

1

International ongoing projects

0

Number of New projects (total)

0

International new projects

1

Number of Active clinical Trials

0

Number of New Clinical Trials

0

Number of Theses

CRIPS has consolidated two emerging new research lines: Gender medicine in infections and effect of aging. Significant differences were identified in risk factors, clinical presentation, outcomes and management issues. These findings have implications in personalized dosage, reduction of adverse events and more sustainable clinical practices. Key highlights should be integrated in the safety culture in the hospital. Understanding inflammaging and immune-senescence may improve quality of life and has implications in personalized vaccine strategies. Interaction with herpes virus and replication of latent cytomegalovirus seems crucial. Leadership in clinical differences between males and females has been endorsed under the framework of infection in the elderly in the ESCMID and the international women in intensive care network.Important multicentre manuscripts were published in pharmacokinetics-pharmacodynamic of antibiotics

CORE/MISSIONS

PROGRAMS

Group Leader

Jordi Rello Condomines

Principal Investigator (PI)

Cristopher Mazo, Joan Balcells Ramirez, Yolanda Peña Lopez

Researchers

Maria Jose Muñoz Blanco, Marta Perez Peña, Miriam Cristina Vah Machado, Tarsila Vieceli

PhD Students

Francesco Romano, Raquel Garcia

Lab Technicians

Veronica Prieto Aguero, Andrea Freixa Benavente, Anna Enrich Font, Beatriz Garcia Lillo

Roberts JA, Ulldemolins M, ... , Rello, J, SMARRT Study investigators
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy
Intensive Care Medicine 2025;51:1628
DOI: 10.1007/s00134-025-08067-w
IF: 21.2

Garin N, Koulenti D, Prendki V, Rello J
Sex-related differences in the management and outcome of intubated adukts with community-acquired pneumona in Europe. A Multicentre study
Eur J Internal Med 2025;139:106406
DOI: 10.1016/j.ejim.2025.06.024
IF: 6.1

Rello J, Soriano JB
Toxic chlorine gas cloud in Vilanova: lessons to learn.
Lancet Resp Med 2025;13:e46
DOI: 10.1016/S2213-2600(25)00196-1
IF: 32.8

Roberts JA, ... Rello J
Are contemporany antifungal doses sufficient for critically ill patients?
Intensive Care Med 2025;51:302-317
DOI: 10.1007/s00134-025-07793-5
IF: 21.2

Alves J, Schouten J, Thursky K, Paz RN, Rello J
Establishing core competences for antimicrobial stewardship teams: a consensus development
Clin Microbiol Infect 2025;31:1313-1320
DOI: 10.1016/j.cmi.2025-04-035
IF: 8.5

PCI Pneumonia
Principal Investigator: Jordi Rello Condomines
Agency: Instituto Salud Carlos III
Funding: 250,000 €
Period: 2023-25

ASCEND
Principal Investigator: Joan Balcells Ramirez
Agency: NIH
Funding: 25,000 €
Period: 2023-25

SARS-CoV2 and other respiratory viruses in childhood
Principal Investigator: Joan Balcells Ramirez
Agency: Insitut Salut Carlos III
Funding: 100,000 €
Period: 2022-25

Festa de la Ciencia
Place: El Born CCM (Barcelona)
Date: 07/09/2025
Brief: Brief exposition.